Treatment of renal disorders, diabetic nephropathy and dyslipidemias
View Patent ↗Disclosed herein are methods, compounds and compositions for preventing or treating a renal disorder or chronic kidney diseases, including nephropathies such as diabetic nephropathy. The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to methods, compounds and compositions for the prevention and/or treatment of for preventing or treating a renal disorder complication. The invention further relates to methods, compounds and compositions for the prevention and/or treatment of dyslipidemia, and more particularly for reducing levels of harmful serum lipid levels, especially cholesterol and triglycerides in diabetic patients.
1. A method for treating diabetic nephropathy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein said compound is 1,3-propanedisulfonic acid sodium salt.
3. The method of claim 1 , wherein clearance of creatinine and/or clearance of uric acid is improved in the subject subsequent to said administration.
4. The method of claim 2 , wherein said compound is 1,3-propanedisulfonic acid disodium salt.
5. The method of claim 2 , wherein clearance of creatinine and/or clearance of uric acid is improved in said subject subsequent to said administration.
6. The method of claim 2 , wherein said subject does not have amyloidosis.
7. The method of claim 6 , wherein said subject does not have AA-amyloidosis.
8. The method of claim 3 , wherein said compound is 1,3-propanedisulfonic acid sodium salt.
9. The method of claim 8 , wherein said compound is 1,3-propanedisulfonic acid disodium salt.
10. The method of claim 3 , wherein said subject does not have amyloidosis.
11. The method of claim 10 , wherein said subject does not have AA-amyloidosis.
12. The method of claim 1 , wherein said wherein said subject does not have amyloidosis.
13. The method of claim 12 , wherein said subject does not have AA-amyloidosis.
14. The method of claim 12 , wherein said compound is 1,3-propanedisulfonic acid sodium salt.
15. The method of claim 14 , wherein said compound is 1,3-propanedisulfonic acid disodium salt.
16. The method of claim 12 , wherein clearance of creatinine and/or clearance of uric acid is improved in said subject subsequent to said administration.
17. The method of claim 1 , wherein said subject does not have AA-amyloidosis.
18. The method of claim 17 , wherein clearance of creatinine and/or clearance of uric acid is improved in said subject subsequent to said administration.
19. The method of claim 17 , wherein said compound is 1,3-propanedisulfonic acid sodium salt.
20. The method of claim 19 , wherein said compound is 1,3-propanedisulfonic acid disodium salt.
21. The method of claim 1 , wherein said compound is 1,3-propanedisulfonic acid disodium salt.
22. The method of claim 21 , wherein clearance of creatinine and/or clearance of uric acid is improved in said subject subsequent to said administration.
23. The method of claim 21 , wherein said subject does not have amyloidosis.
24. The method of claim 23 , wherein said subject does not have AA-amyloidosis.
25. The method of claim 1 , wherein said therapeutically effective amount is 400 mg, 800 mg or 1,200 mg BID.